Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigator-Sponsored Phase 2 Study of Single Agent Selinexor (KPT-330) in Patients With Relapsed Small Cell Lung Cancer

NCT02351505 is registered in ClinicalTrials.gov with Erin Bertino as lead sponsor.

NCT NCT02351505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02351505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigator-Sponsored Phase 2 Study of Single Agent Selinexor (KPT-330) in Patients With Relapsed Small Cell Lung Cancer
Lead sponsor
Erin Bertino
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2015
Completion date
March 31, 2016
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent small cell lung carcinoma